Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shareholders with losses exceeding $50,000 are encouraged to contact the firm.   BENSALEM, Pa.

CTLT Investors Have Opportunity to Lead Catalent, Inc. Securities Fraud Lawsuit

NEW YORK , April 19, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Catalent, Inc.. Shareholders who purchased shares of CTLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Catalent, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 25, 2023 - (NYSE: CTLT)

NEW YORK , April 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalent, Inc. - CTLT

A pair of analysts cut their price targets on the shares. One of the cuts was rather aggressive.

Why Catalent Stock Dove More Than 7% Today

Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.

Catalent (CTLT) Declines on Profit Warnings and CFO Exit

A media report said that a potential suitor has abandoned its efforts to acquire the specialty healthcare services provider. That party isn't entirely giving up on its chase, however.

Why Catalent Stock Slumped on Monday

NEW ORLEANS , April 14, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 25, 2023 to file lead plaintiff applications in a securities class action lawsuit against Catalent, Inc. (the "Company") (NYSE: CTLT), if they purchased the Company's securities between August 30, 2021 and October 31, 2022, inclusive (the "Class Period").

CATALENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Catalent, Inc. - CTLT

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period"), of the important April 25, 2023, lead plaintiff deadline.

ROSEN, A TOP RANKED FIRM, Encourages Catalent, Inc. Investors to Secure Counsel Before Important April 25 Deadline in Securities Class Action - CTLT

Shares of the contract drug manufacturer plummet Friday in their largest percentage decrease on record, based on data back to July 2014.

Catalent Issues a Profit Warning. The Stock Is S&P 500's Leading Decliner.

Catalent has warned its financial performance is set to be impacted by productivity issues and higher-than-expected costs at three of its facilities, including two of its largest manufacturing facilities, sending its stock tumbling by more than 25%.  The contract drug manufacturer said on Friday that it expects its financial results for the third fiscal quarter and outlook for the remainder of the 2023 fiscal year will be adversely impacted by the issues.

Catalent warns of profit hit from manufacturing issues, stock tumbles 25%

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Catalent, Inc. (NYSE: CTLT). The class action is on behalf of shareholders who purchased Catalent securities between August 30, 2021 and October 31, 2022, inclusive (the “Class Period”). Investors are hereby notified that they have until April 25, 2023, to move the Court to serve as lead plaintiff in this action.

Catalent (CTLT) News Update: Johnson Fistel Urges Shareholders to Join Class Action Lawsuit and Provides New Update

Catalent Inc.'s stock CTLT, -1.46% tumbled 20% in premarket trade Friday, after the provider of services to the pharma industry issued a profit warning for its fiscal third quarter through March 31. The Somerset, N.J.

Catalent issues profit warning for fiscal Q3 after manufacturing and cost issues at three plants, sending stock down 20%

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced a business update.

Catalent Provides Business Update and Names Ricky Hopson as Interim Chief Financial Officer

NEW YORK--(BUSINESS WIRE)---- $CTLT #CTLT--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and October 31, 2022, both dates inclusive (the “Class Period”), of the important April 25, 2023, lead plaintiff deadline. SO WHAT: If you purchased Catalent securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CTLT INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Catalent, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CTLT

NEW ORLEANS , April 7, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 25, 2023 to file lead plaintiff applications in a securities class action lawsuit against Catalent, Inc. (the "Company") (NYSE: CTLT), if they purchased the Company's securities between August 30, 2021 and October 31, 2022, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of New Jersey.

CATALENT SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Catalent, Inc. - CTLT

NEW YORK , April 4, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period"), of the important April 25, 2023, lead plaintiff deadline. SO WHAT: If you purchased Catalent securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Catalent, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CTLT

NEW ORLEANS , March 31, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 25, 2023 to file lead plaintiff applications in a securities class action lawsuit against Catalent, Inc. (the "Company") (NYSE: CTLT), if they purchased the Company's securities between August 30, 2021 and October 31, 2022, inclusive (the "Class Period").

CATALENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Catalent, Inc. - CTLT

Intel

Warner Bros Discovery Inc

Investors enjoyed a small S&P 500 rally in March. But there were much more lucrative places to put money in the month.

Three Stocks Turn $10,000 To $25,265 In Just 3 Months

Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.

Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials

NEW YORK , March 28, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period"), of the important April 25, 2023, lead plaintiff deadline. SO WHAT: If you purchased Catalent securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Catalent, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CTLT

NEW ORLEANS , March 24, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 25, 2023 to file lead plaintiff applications in a securities class action lawsuit against Catalent, Inc. (the "Company") (NYSE: CTLT), if they purchased the Company's securities between August 30, 2021 and October 31, 2022, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of New Jersey.

CATALENT SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Catalent, Inc. - CTLT

Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.

Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses

NEW YORK , March 21, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period"), of the important April 25, 2023, lead plaintiff deadline. SO WHAT: If you purchased Catalent securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Catalent, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CTLT

Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.

Catalent (CTLT) Inks Deal for New & Effective Drug Delivery

Catalent's COVID-19 related revenues have fallen, but cushioned by growth in other areas and they continue to expand their activities. A lawsuit over accusations of misleading investors is ongoing that could grow to be a headache.

News for Catalent Stock (CTLT)